Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent cliffs, product recalls, and opioid litigation make Teva Pharmaceutical Industries’ disclosures uniquely dense. Digging through a 300-page document for segment margins or litigation reserves is tedious. That’s why investors search for TEVA SEC filings explained simply—and why Stock Titan’s AI turns raw EDGAR data into clear insights you can trust.
Our platform streams every filing the minute it hits EDGAR and pairs it with AI-powered summaries, key-metric tables, and risk flags. Whether you need a TEVA quarterly earnings report 10-Q filing or want to monitor TEVA Form 4 insider transactions real-time, we’ve got you covered. Here’s what you’ll find:
- 10-K & 10-Q—full text plus a TEVA annual report 10-K simplified dashboard and deep TEVA earnings report filing analysis.
- Form 4—alerts on TEVA insider trading Form 4 transactions and granular views of TEVA executive stock transactions Form 4.
- 8-K—real-time headlines with TEVA 8-K material events explained, from FDA warning letters to debt covenant updates.
- DEF 14A—a concise take on the TEVA proxy statement executive compensation discussion and board governance shifts.
Need help understanding TEVA SEC documents with AI? Stock Titan highlights how pricing pressure impacts cash flow, where biosimilar milestones sit, and when litigation accruals change. Professionals use these insights to track segment performance, spot option grants before approval catalysts, and compare R&D outlays quarter to quarter—without wading through endless footnotes.
David R. McAvoy, identified as an Executive Vice President and Chief Legal Officer of Teva Pharmaceutical Industries Ltd. (TEVA), reported an open-market purchase of 1,113 ordinary shares on 09/05/2025 at a price of $18.8572 per share. After the transaction McAvoy beneficially owns 13,027 ordinary shares. The filing notes that the ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
The Form 4 was signed on behalf of McAvoy by an attorney-in-fact and filed under Section 16 reporting requirements. The report contains no other derivative transactions or additional disclosures.
FAQ
What is the current stock price of Teva Pharm (TEVA)?
What is the market cap of Teva Pharm (TEVA)?
